HitGen-Oligonucleotides

Oligonucleotides

HitGen offers comprehensive solutions for the development of oligonucleotide therapeutics, covering the entire process from research and development to production.

Nucleic Acid Sequence Design: HitGen accelerates lead compound identification through its AI-powered oligonucleotide platform, enabling multi-dimensional sequence-structure-function modeling integrated with machine learning-driven lead prioritization.

Monomer and Solid Support Chemistry: HitGen has experience on a series of unconventional natural nucleoside compound modification methods, including stereo- and enantio-selective reactions and is able to obtain the modified nucleoside compounds in a time and cost effective manner.

Oligonucleotide Chemistry: As an open and integrated platform, the nucleic acid chemical synthesis platform of Hitgen has leading technological, human - resource and platform - based advantages. It can meet the diverse needs of different market environments and various partners, empowering the R & D of nucleic acid drugs!

Nucleic Acid Delivery: HitGen offers discovery services or direct licensing for hepatic and extrahepatic delivery systems. The platform provides customized delivery solutions to empower efficient nucleic acid drug development and accelerate the translation process from laboratory research to clinical applications.

Medicinal Chemistry: HitGen offers chemical modification solutions for discovery project of nucleic acid drug, enhancing druggability while maintaining activity. We aim to accelerates the entire development cycle of nucleic acid therapeutics, empowering global innovation in pharmaceutical R&D.

Biological Evaluation: HitGen offers comprehensive development and evaluation capabilities, including cell line or primary cell based screening, in vivo efficacy models (HDI and AAV humanized mouse models), DMPK, and toxicology studies.

CDMO: Relying on a 2000㎡ oligonucleotide GMP workshop, 1000㎡ quality control laboratory, and HitGen's professional R&D laboratories, Hitston has achieved gram-to-kilogram-scale API production for IND applications, clinical Phase I-III, and early commercialization stages, with a total investment of nearly 100 million RMB, covering global demand.

Thanks for reading!

For more details on how we can advance your innovative drug discovery projects

Sites: HitGen Inc.

Building C2, NO.8, Huigu 1st East Road
Tianfu International Bio-Town,
Shuangliu District, Chengdu City,
Sichuan Province,P.R. China

Tel : +86-28-8519-7385

HitGen Pharmaceuticals Inc.(US Subsidiary)

Tel : +1-(508)-840-9646

Vernalis (R&D) Limited (UK Subsidiary)

Granta Park,Great Abington
Cambridge,CB21 6GB
United Kingdom

Tel : +44(0)1223-895555

Contact: Business Inquiry : bd@hitgen.com; Investor Relations : investors@hitgen.com; Media : media@hitgen.com; Career and Jobs : human.resources@hitgen.com

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information

↑